Phase III PEMPHIX study shows Roche’s MabThera/Rituxan (rituximab) superior to MMF
Roche announced data from the Phase III PEMPHIX study evaluating efficacy and safety of MabThera®/Rituxan® (rituximab) compared to mycophenolate mofetil in adults with moderate to severe pemphigus vulgaris. The study met the primary endpoint at Week 52. October 14, 2019